ArticleCancer research2016

Correction: Combining miR-10b-Targeted Nanotherapy with Low-Dose Doxorubicin Elicits Durable Regressions of Metastatic Breast Cancer.

PubMed ↗Publisher ↗

No numbers read from the abstract.